Table 1 Baseline characteristics of enrolled patients and Cox survival analysis for risk of HCC
Variables | Valuea | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | ||
Gender, female | 47 (18.7%) | 0.524(0.271–1.014) | 0.055 | 0.566(0.290–1.105) | 0.095 |
Age(years) | 47.4 (45.9–48.9) | 1.009(0.991–1.028) | 0.337 | ||
ALT (IU/L), <40 | 114 | ||||
40–160 | 82 | 1.534(0.773–3.047) | 0.221 | ||
> = 160 | 46 | 1.234(0.597–2.550) | 0.571 | ||
TBA(μmol/L), <10 | 84 | ||||
10–100 | 91 | 2.267(1.324–3.882) | 0.003 | 1.918(1.111–3.310) | 0.019 |
> = 100 | 68 | 2.218(1.231–3.997) | 0.008 | 1.654(0.897–3.053) | 0.107 |
APRI, <0.5 | 40 | ||||
0.5–1.5 | 79 | 0.815(0.424–1.568) | 0.541 | ||
> = 1.5 | 110 | 1.304(0.825–2.061) | 0.256 | ||
DNA(IU/ml), <5a102 | 136 | ||||
5a102–106 | 44 | 1.421(0.608–3.320) | 0.417 | ||
> = 106 | 23 | 1.819(0.742–4.459) | 0.191 | ||
HBsAg, positive | 198 | 0.529(0.244–1.147) | 0.107 | ||
HBeAg, positive | 46 | 1.425(0.654–3.103) | 0.373 | ||
PIVKA-II(mAU/ml), <200 | 169 | 0.402(0.260–0.621) | 0.000 | 0.433(0.277–0.678) | 0.000 |
AFP(ng/ml), <20 | 115 | ||||
20–200 | 72 | 0.641(0.379–1.087) | 0.099 | 0.611(0.357–1.045) | 0.072 |
> = 200 | 42 | 0.700(0.391–1.251) | 0.228 | 0.754(0.411–1.383) | 0.362 |